Investigational Drug Details
| Drug ID: | D324 |
| Drug Name: | Seladelpar |
| Synonyms: | MBX-8025 |
| Type: | Chemical drug |
| DrugBank ID: | DB12390 |
| DrugBank Description: | Seladelpar (MBX-8025) has been used in trials studying the treatment of Hyperlipidemia. |
| PubChem ID: | 11236126 |
| CasNo: | 851528-79-5 |
| Repositioning for NAFLD: | No |
| SMILES: | CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC1=CC(C)=C(OCC(O)=O)C=C1 |
| Structure: |
|
| InChiKey: | JWHYSEDOYMYMNM-QGZVFWFLSA-N |
| Molecular Weight: | 444.471 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 terminated (NCT03551522: unexpected histological findings) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0239 | NCT03551522 | Phase 2 | Terminated | No Results Available | April 30, 2018 | January 11, 2022 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A31979 | 29404484 | Hepatol Commun | The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. | Details |
| A49895 | 35605662 | J Biol Chem | Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. | Details |
| A50106 | 35525796 | Pathology | Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis. | Details |
| A51306 | 35735253 | Hepatol Commun | Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. | Details |